Welcome to our dedicated page for Kiora Pharma SEC filings (Ticker: KPHMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kiora Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kiora Pharma's regulatory disclosures and financial reporting.
Kiora Pharmaceuticals reported first quarter 2026 results, highlighting clinical progress in its retinal disease pipeline and a modestly higher net loss. The company recorded a net loss of $2.4 million for the quarter, or $0.58 per basic and diluted share.
Kiora ended March 31, 2026 with $13.9 million in cash and short-term investments and subsequently raised an additional $5.0 million through a strategic equity financing. Management believes this supports an operational runway into late 2028, beyond anticipated data readouts from its KIO-301 ABACUS-2 and KIO-104 KLARITY Phase 2 trials.
Enrollment in ABACUS-2 for KIO-301 is roughly half complete, supported by strong patient demand and expanded trial sites, and prior ABACUS-1 data were published in Nature Medicine. KIO-104 continues in the KLARITY study, with a planned safety review expected to enable escalation to a higher dose cohort.
Kiora Pharmaceuticals reported first quarter 2026 results, highlighting clinical progress in its retinal disease pipeline and a modestly higher net loss. The company recorded a net loss of $2.4 million for the quarter, or $0.58 per basic and diluted share.
Kiora ended March 31, 2026 with $13.9 million in cash and short-term investments and subsequently raised an additional $5.0 million through a strategic equity financing. Management believes this supports an operational runway into late 2028, beyond anticipated data readouts from its KIO-301 ABACUS-2 and KIO-104 KLARITY Phase 2 trials.
Enrollment in ABACUS-2 for KIO-301 is roughly half complete, supported by strong patient demand and expanded trial sites, and prior ABACUS-1 data were published in Nature Medicine. KIO-104 continues in the KLARITY study, with a planned safety review expected to enable escalation to a higher dose cohort.
Kiora Pharmaceuticals, Inc. reported a net loss of $2.4 million for the three months ended March 31, 2026, compared with $2.2 million a year earlier, as it continues investing in ophthalmic drug development.
Total operating expenses were $2.5 million, including $1.6 million in general and administrative costs and $2.1 million in research and development, partly offset by $1.2 million of collaboration credits tied to the KIO‑301 program. Other income, mainly interest, added $0.1 million.
At March 31, 2026, Kiora held $11.0 million in cash and cash equivalents and $2.9 million in short‑term investments, with total assets of $21.2 million and stockholders’ equity of $13.9 million. Management states that, including $5 million raised in an April 2026 private placement and reimbursement of all KIO‑301 expenses by partner Théa Open Innovation, current resources are expected to fund planned operations into late 2028.
Kiora Pharmaceuticals, Inc. reported a net loss of $2.4 million for the three months ended March 31, 2026, compared with $2.2 million a year earlier, as it continues investing in ophthalmic drug development.
Total operating expenses were $2.5 million, including $1.6 million in general and administrative costs and $2.1 million in research and development, partly offset by $1.2 million of collaboration credits tied to the KIO‑301 program. Other income, mainly interest, added $0.1 million.
At March 31, 2026, Kiora held $11.0 million in cash and cash equivalents and $2.9 million in short‑term investments, with total assets of $21.2 million and stockholders’ equity of $13.9 million. Management states that, including $5 million raised in an April 2026 private placement and reimbursement of all KIO‑301 expenses by partner Théa Open Innovation, current resources are expected to fund planned operations into late 2028.
Kiora Pharmaceuticals is asking stockholders to vote at its 2026 annual meeting on director elections, executive pay, auditor ratification, and an equity plan increase. Three Class II directors are nominated to serve until 2029. Investors will cast a non-binding advisory vote on 2025 compensation for the CEO and other named executives, and on retaining Haskell & White LLP as independent auditor for 2026. The company also seeks approval to amend its 2024 Equity Incentive Plan to add 1,500,000 shares for future equity awards. As of the April 16, 2026 record date, 4,432,440 common shares were outstanding, each with one vote.
Kiora Pharmaceuticals is asking stockholders to vote at its 2026 annual meeting on director elections, executive pay, auditor ratification, and an equity plan increase. Three Class II directors are nominated to serve until 2029. Investors will cast a non-binding advisory vote on 2025 compensation for the CEO and other named executives, and on retaining Haskell & White LLP as independent auditor for 2026. The company also seeks approval to amend its 2024 Equity Incentive Plan to add 1,500,000 shares for future equity awards. As of the April 16, 2026 record date, 4,432,440 common shares were outstanding, each with one vote.
Kiora Pharmaceuticals entered into a private placement with institutional investors Perceptive Advisors and ADAR1 Capital Management, raising $5.0 million upfront and providing up to an additional $19.0 million in potential warrant exercise proceeds. The deal includes 438,471 common shares, pre-funded warrants for 1,527,711 shares, and Tranche A-1 and A-2 warrants for up to 9,830,909 additional shares at an exercise price of $1.94 per share. Warrants are immediately exercisable and have milestone-based terms tied to strategic transactions and completion of Phase 3 trial enrollment. The securities were issued under Regulation D exemptions and will later be registered for resale under a planned registration statement.
Kiora Pharmaceuticals entered into a private placement with institutional investors Perceptive Advisors and ADAR1 Capital Management, raising $5.0 million upfront and providing up to an additional $19.0 million in potential warrant exercise proceeds. The deal includes 438,471 common shares, pre-funded warrants for 1,527,711 shares, and Tranche A-1 and A-2 warrants for up to 9,830,909 additional shares at an exercise price of $1.94 per share. Warrants are immediately exercisable and have milestone-based terms tied to strategic transactions and completion of Phase 3 trial enrollment. The securities were issued under Regulation D exemptions and will later be registered for resale under a planned registration statement.
Kiora Pharmaceuticals CFO Melissa Tosca reported a routine tax-related share disposition. On April 1, 2026, 929 shares of Kiora Pharmaceuticals common stock were delivered at $1.95 per share to pay an exercise price or tax liability. After this tax-withholding disposition, Tosca directly holds 26,975 shares of common stock, indicating the transaction affected only a small portion of her position and was not an open-market sale.
Kiora Pharmaceuticals CFO Melissa Tosca reported a routine tax-related share disposition. On April 1, 2026, 929 shares of Kiora Pharmaceuticals common stock were delivered at $1.95 per share to pay an exercise price or tax liability. After this tax-withholding disposition, Tosca directly holds 26,975 shares of common stock, indicating the transaction affected only a small portion of her position and was not an open-market sale.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a tax-related share disposition. On the transaction date, 929 shares of Kiora Pharmaceuticals common stock were withheld at $1.95 per share to cover tax obligations. After this non-open-market tax-withholding disposition, Daniels directly held 31,741 shares of common stock.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a tax-related share disposition. On the transaction date, 929 shares of Kiora Pharmaceuticals common stock were withheld at $1.95 per share to cover tax obligations. After this non-open-market tax-withholding disposition, Daniels directly held 31,741 shares of common stock.
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related share disposition. On April 1, 2026, he transferred 1,906 shares of Common Stock at $1.95 per share to cover taxes by delivering shares instead of cash. After this tax-withholding disposition, he directly holds 60,692 shares of Kiora common stock. This was not an open-market sale or purchase but a routine mechanism tied to equity compensation.
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related share disposition. On April 1, 2026, he transferred 1,906 shares of Common Stock at $1.95 per share to cover taxes by delivering shares instead of cash. After this tax-withholding disposition, he directly holds 60,692 shares of Kiora common stock. This was not an open-market sale or purchase but a routine mechanism tied to equity compensation.
Kiora Pharmaceuticals announced that Chief Development Officer Eric J. Daniels, M.D., MBA will resign effective April 17, 2026 to pursue another opportunity. The company stated his departure is not due to any disagreement over operations, policies, or practices and has begun a search for his successor.
Kiora emphasized continued progress in its retinal disease pipeline. In the ABACUS-2 Phase 2 trial of KIO-301, a planned safety review allowed enrollment of remaining patients in the 50µg dose cohort and cleared initiation of the 100µg cohort. In the KLARITY Phase 2 trial of KIO-104, all planned safety checkpoints have been cleared and patient enrollment is ongoing.
Kiora Pharmaceuticals announced that Chief Development Officer Eric J. Daniels, M.D., MBA will resign effective April 17, 2026 to pursue another opportunity. The company stated his departure is not due to any disagreement over operations, policies, or practices and has begun a search for his successor.
Kiora emphasized continued progress in its retinal disease pipeline. In the ABACUS-2 Phase 2 trial of KIO-301, a planned safety review allowed enrollment of remaining patients in the 50µg dose cohort and cleared initiation of the 100µg cohort. In the KLARITY Phase 2 trial of KIO-104, all planned safety checkpoints have been cleared and patient enrollment is ongoing.
Kiora Pharmaceuticals reported a net loss of $10.8 million for 2025, compared with net income of $3.6 million in 2024, mainly because 2024 included $16.0 million of collaboration revenue and 2025 recorded a $4.6 million in-process R&D impairment related to KIO-104.
Revenue was zero in 2025, while operating expenses rose as R&D increased to $10.8 million with two Phase 2 trials underway and G&A reached $5.7 million. Kiora ended 2025 with $17.1 million in cash, cash equivalents and short-term investments plus $3.5 million in receivables and projects its cash runway into late 2027.
Pipeline progress included advancing KIO-301 and KIO-104 into active Phase 2 studies in retinal diseases and signing an option agreement with Senju Pharmaceutical with potential value of up to $110 million plus royalties, alongside continued work on the KIO-300 ion-channel modulator platform.
Kiora Pharmaceuticals reported a net loss of $10.8 million for 2025, compared with net income of $3.6 million in 2024, mainly because 2024 included $16.0 million of collaboration revenue and 2025 recorded a $4.6 million in-process R&D impairment related to KIO-104.
Revenue was zero in 2025, while operating expenses rose as R&D increased to $10.8 million with two Phase 2 trials underway and G&A reached $5.7 million. Kiora ended 2025 with $17.1 million in cash, cash equivalents and short-term investments plus $3.5 million in receivables and projects its cash runway into late 2027.
Pipeline progress included advancing KIO-301 and KIO-104 into active Phase 2 studies in retinal diseases and signing an option agreement with Senju Pharmaceutical with potential value of up to $110 million plus royalties, alongside continued work on the KIO-300 ion-channel modulator platform.
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on therapies for retinal diseases. Its lead candidate, KIO-301, is a small-molecule “photoswitch” being developed for late-stage retinitis pigmentosa and other inherited retinal dystrophies. A Phase 1b trial showed safety and vision-related improvements, and a 36‑patient Phase 2 ABACUS‑2 trial in RP is enrolling under a global co-development agreement with Théa Open Innovation, which funds all KIO‑301 R&D.
The company is also advancing KIO-104, an intravitreal DHODH inhibitor for retinal inflammation such as diabetic macular edema and posterior non‑infectious uveitis, with a Phase 2 KLARITY trial dosing patients. A topical DHODH inhibitor, KIO‑101, is being positioned for partnering in ocular manifestations of autoimmune diseases. Kiora reported a $10.8 million net loss for the year ended December 31, 2025, versus net income of $3.6 million in 2024, and held $17.1 million in cash and short-term investments, which it expects to fund operations into late 2027. As of March 21, 2026, there were 3,950,628 shares of common stock outstanding.
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on therapies for retinal diseases. Its lead candidate, KIO-301, is a small-molecule “photoswitch” being developed for late-stage retinitis pigmentosa and other inherited retinal dystrophies. A Phase 1b trial showed safety and vision-related improvements, and a 36‑patient Phase 2 ABACUS‑2 trial in RP is enrolling under a global co-development agreement with Théa Open Innovation, which funds all KIO‑301 R&D.
The company is also advancing KIO-104, an intravitreal DHODH inhibitor for retinal inflammation such as diabetic macular edema and posterior non‑infectious uveitis, with a Phase 2 KLARITY trial dosing patients. A topical DHODH inhibitor, KIO‑101, is being positioned for partnering in ocular manifestations of autoimmune diseases. Kiora reported a $10.8 million net loss for the year ended December 31, 2025, versus net income of $3.6 million in 2024, and held $17.1 million in cash and short-term investments, which it expects to fund operations into late 2027. As of March 21, 2026, there were 3,950,628 shares of common stock outstanding.